EGFR and non-small cell lung carcinoma: This test granted FDA approval on 1 June 2016, being the first test employing liquid biopsy for the detection of EGFR exon 19 deletions or exon 21 (L858R) mutations in patients with metastatic NSCLC eligible for treatment with erlotinib.